Docket No.: 20052/1200522-US1

LISTING OF THE CLAIMS

The following listing of the claims replaces all prior claims in the application:

1. (Currently Amended) A method for inducing T-cell tolerance or non- responsiveness of donor T-cells to desired alloantigen-bearing cells *ex vivo* comprising the following:

- (i) providing a culture containing donor tissue containing donor T-cells;
- (ii) producing a mixed lymphocyte reaction culture by adding to said donor T-cell culture alloantigen-bearing cells obtained from a recipient;
- (iii) adding an anti-gp39 antibody or a gp39-binding fragment thereof to the resultant mixed lymphocyte reaction culture;
- (iv) maintaining these cells in the mixed lymphocyte reaction culture ex vivo for a sufficient time to render the donor T-cells substantially tolerant or non-responsive to said alloantigen-bearing cells, and
- (v) assaying ex vivo for induction of donor T-cell tolerance or non-responsiveness.
- 2. (Original) The method of Claim 1, wherein the tissue containing donor T-cells is donor bone marrow or peripheral blood cells.
 - 3. (Canceled)
- 4. (Currently amended) The method of Claim 1, wherein the gp39 antagonist antibody is an anti-human gp39 monoclonal antibody.
- 5. (Previously Presented) The method of Claim 4, wherein said anti-gp39 antibody is a chimeric or humanized anti-human gp39 monoclonal antibody.
- 6. (Currently amended) The method of Claim 1, wherein the donor T-cells are cultured in step iv (iv) for a time ranging from about 1 to 30 days.

Docket No.: 20052/1200522-US1

8. (Currently Amended) The method of Claim 1, wherein the alloantigen-bearing cells comprise cells or tissue obtained from a potential transplant recipient that has have been treated to deplete recipient T-cells.

- 9. (Previously Presented) The method of Claim 8, wherein recipient T-cell depletion is effected by irradiation.
- 10. (Currently Amended) The method of Claim 1, wherein the donor T-cells that have been determined to be tolerized by the assay of step (v) are transplanted into a recipient in need of such transplantation.
- 11. (Original) The method of Claim 10, wherein the recipient is in need of immune reconstitution as a result of disease or disease treatment.

12. (Canceled)

- 13. (Currently amended) The method of Claim 1, wherein the step of assaying for induction of donor T-cell tolerance or non-responsiveness comprises measuring IL-2 concentration in the cell culture medium supernatants of the donor T-cells cultured in step iv (iv) and of control donor T-cells, wherein detection of reduced IL-2 concentration in the supernatant of the donor T-cells cultured in step iv (iv), relative to that of the IL-2 concentration in the supernatant of the control T-cells, is indicative of substantial donor T-cell tolerance or non-responsiveness to the alloantigen-bearing cells.
- 14. (Withdrawn) The method of Claim 1, wherein the step of assaying for induction of donor T-cell tolerance or non-responsiveness comprises measuring the concentration of interferongamma in the cell culture medium supernatants of the donor T-cells cultured in step iv and of control donor T-cells,

wherein detection of reduced interferon-gamma concentration in the supernatant of the donor T-cells cultured in step iv relative to that of the control T-cells is indicative of substantial donor T-cell tolerance or non-responsiveness to the alloantigen-bearing cells.

Docket No.: 20052/1200522-US1

15. (Withdrawn) The method of Claim 1, wherein the step of assaying for induction of donor T-cell tolerance or non-responsiveness comprises assaying to detect at least one antigen selected from the group consisting of L-selectin, ICAM-1, and CD45 in the donor T-cells cultured in step iv and control donor T-cells,

wherein detection of an increased amount of L-selectin or ICAM-1, or a reduced amount of CD45 in the donor T-cells cultured in step iv relative to that in the control donor T-cells is indicative of substantial donor T-cell tolerance or non-responsiveness to the alloantigen-bearing cells.